Amgen Inc. (formerly Applied Molecular Genetics Inc.) is one of the world’s largest independent biotechnology companies established at Thousand Oaks, California, in 1980.
- In Sep 2019, Hummingbird signs collaboration with Amgen to co-discover novel therapeutics using Hummingbird’s Rational Antibody Discovery Platform. Under the terms, Amgen to provide Hummingbird with two of its proprietary targets and allows for further expansion of up to 10 additional targets over a 6-year period upon which Hummingbird will apply its proprietary Rational Antibody Discovery platform to create novel therapeutic antibodies. Amgen has an exclusive option to license rights to the resulting antibodies from each project. Hummingbird will receive upfront and research payments and, upon entry into a license agreement, is also eligible to receive downstream clinical and commercial milestone payments of up to $100 Mn per program plus royalties. Additional financial details remains undisclosed.
- In Oct 2019, Amgen enters Into strategic collaboration with BeiGene to expand Oncology presence In China. Under the agreement, BeiGene to commercialize XGEVA® (denosumab), KYPROLIS® (carfilzomib) and BLINCYTO® (blinatumomab) in China during which time the parties will equally share profits and losses. Also, Amgen and BeiGene will collaborate to advance 20 medicines from Amgen’s innovative oncology pipeline in China and globally. BeiGene will share global research and development costs and contribute up to $1.25 billion to advance these medicines. Amgen will pay royalties to BeiGene on the sales of these products outside of China, with the exception of AMG 510, Amgen’s first-in-class KRASG12C inhibitor that is being studied as a potential treatment for solid tumors.
- In Feb 2019, Abilita Bio entered into a multi-target research collaboration agreement with Amgen. Under the terms of the agreement, Abilita Bio will leverage its proprietary Enabled Membrane Protein (EMP™) technology platform to support Amgen’s R&D efforts on challenging integral membrane protein targets. Financial details were not disclosed.
- In 2019, Jasper Therapeutics secured worldwide rights to JSP191 (formerly AMG191) from Amgen.
In 2018, Amgen founded Kartos a special purpose comapny spinoff from Amgen, for the further clinical development of AMG-232 / KRT-232. - In Dec 2018, Amgen obtains exclusive global development and commercial rights of Molecular Partner’s preclinical FAP x 4-1BBmulti-specific DARPin® molecule – MP0310 (now AMG 506). Under the terms, Amgen paid $50 Mn in upfront payment and Molecular Partners is also eligible to receive up to $497 Mn in development, regulatory and commercial milestone payments, as well as double-digit, tiered royalties on sales.
- In Oct 2017, Amgen and CytomX entered into a strategic collaboration to co-develop a CytomX Probody™ T-cell engaging bispecific against EGFRxCD3 with CytomX leading early development. Amgen will lead later development and commercialization with global late-stage development costs shared between the two companies. Amgen paid $40 Mn in an upfront payment and purchase $20 Mn of CytomX stock. CytomX will be eligible to receive up to $455 Mn in development, regulatory and commercial milestones for the EGFR program. Amgen will lead global commercial activities with CytomX able to opt into a profit share in the U.S. and receive tiered, double-digit royalties on net product sales outside of the U.S. Amgen will also receive exclusive worldwide rights to develop and commercialize up to three additional, undisclosed targets. Should Amgen ultimately pursue all of these targets, CytomX will be eligible to receive up to $950 Mn in additional upfront and milestone payments and high single-digit to mid-double digit royalty payments on any resulting products. CytomX will also receive the rights from Amgen to an undisclosed preclinical T-cell engaging bispecific program; Amgen is eligible to receive milestones and royalty payments on any resulting products from this CytomX program.
- In Jan 2017, Amgen and Immatics Biotechnologies GmbH, signed license agreement to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers by combining Immatics’ XPRESIDENT® target discovery and T-cell receptor (TCR) capabilities with Amgen’s validated Bispecific T-cell Engager (BiTE®) technology to develop novel oncology drugs. Under the terms, Amgen will be responsible for the clinical development, manufacturing and commercialization worldwide, while Immatics to receive an upfront fee of $30 Mn and is eligible to receive over $500 Mn in development, regulatory and commercial milestone payments for each program and tiered royalties up to a double-digit percentage of net sales.
- In Sep 2016, Genenta, San Raffaele and Amgen partnered to evaluate myeloid-targeted hematopoietic stem cell (HSC) therapies to treat cancer. The partners will use Genenta’s HSC platform, which it licensed from San Raffaele. The other details remains undisclosed.
- In Sep 2015, Amgen and Xencor, Inc. entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation by combining Amgen’s capabilities in target discovery and protein therapeutics with Xencor’s XmAb® bispecific technology platform. The agreement also includes a preclinical bispecific T cell engager program directed at CD38 and CD3 for multiple myeloma. Under the terms, Xencor received a $45 Mn upfront payment and up to $1.7 billion in clinical, regulatory and sales milestone payments in total for the six programs. Xencor is eligible to receive mid to high single-digit royalties for candidates directed against Amgen’s targets, and high single to low double-digit royalties for Xencor’s CD38 bispecific T cell engager.
- Amgen is also in collaboration with ImmunoGen for developing mAbs using its Targeted Antibody Payload (TAP) technology.
Page 2 of 3
